Over the past year, ANCA Vasculitis News has brought you coverage of the latest developments in research related to ANCA-associated vasculitis (AAV). We look forward to continuing to bring you news about advances in research and treatment in the new year. Here we have compiled a list of the top…
Adding a low dose of cyclophosphamide to rituximab for remission induction was safe and more effective at preventing relapses in the first two years in people with severe ANCA-associated vasculitis (AAV) than rituximab alone, a new study shows. No significant benefit was observed in the combination treatment after five years.
Blood levels of the soluble forms of CD28 and TIM-3 — two receptor proteins involved in the regulation of immune responses — are significantly associated with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) activity, a study showed. The levels of these so-called immune checkpoint molecules were increased in people with active AAV…
Hepatitis E infection can be effectively managed in people with ANCA-associated vasculitis (AAV) by pausing immunosuppressive therapy, though patients may experience AAV flares during this pause, a new study shows. “Despite potent immunosuppression before infection, all patients cleared the virus after cessation of the immunosuppressant without additional anti-viral therapy.
A 13-year-old girl developed ANCA-associated vasculitis (AAV) with major involvement of the central nervous system after COVID-19, a case study reports. “To our knowledge, this is the first reported pediatric case of ANCA-associated vasculitis with predominant central nervous system involvement after COVID-19 infection,” the researchers wrote. The girl had…
A 25-year-old man was diagnosed with eosinophilic granulomatosis with polyangiitis (EGPA) after going to an outpatient clinic with joint pain and numbness in the hands and legs, according to a case study. He received treatment with corticosteroids and immunosuppressants, which stopped the EGPA progression and eased peripheral…
The CoronaVac COVID-19 vaccine has an excellent safety profile, but generates only a moderate immune response in people with ANCA-associated vasculitis (AAV), a clinical trial analysis found. Although the levels of vaccine-induced antibodies against SARS-CoV-2, the virus that causes COVID-19, declined over six months, a booster shot was shown…
Monocytes, a type of white blood cell, that carry a protein called CD206 are found at abnormally high levels in the blood of people with active ANCA-associated vasculitis (AAV), a study has found. This held true even when researchers compared people with AAV who had glomerulonephritis, a condition in…
Patients with active ANCA-associated vasculitis (AAV) can be distinguished from those who are in remission by the presence of different subsets of a type of immune cell known as regulatory T-cells, or Tregs, a new study reported. Reduced functionality of these regulatory immune cells had been previously implicated in…
People with ANCA-associated vasculitis (AAV) are at an increased risk of experiencing cardiovascular problems, such as a stroke, according to a new study done in South Korea. Indeed, AAV patients were found to have a more than two times higher risk of cardiovascular health problems than individuals without any…
Get regular updates to your inbox.